Physiological significance of big mitogen-activated protein kinase 1 in metabolic syndrome
Physiological significance of big mitogen-activated protein kinase 1 in metabolic syndrome
批准号:
18590238
负责人:
YOSHIZUMI Masanori
金额:
$2.57万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007
中文摘要
点击翻译按钮获取中文摘要
英文摘要
In the current research project, we investigated the physiological significance of big mitogen-activated protein kinase 1 in metabolic syndrome using the model animals of diabetic rats and cultured cells.1) In the type 2 diabetic rat model OLETF, BMK1 was activated in vascular smooth muscles of small arteries. Similar results were obtained in the atherosclerotic model mice at the site of adventitia of cuff-injured femoral artery. From these findings, it was suggested that BMK1 activation is involved in the pathogenesis of diabetic microangiopathy.2) In experiments using cultured rat aortic smooth muscle cells (RASMC), platelet-derived growth factor (PDGF) stimulated BMK1 activation in a time and concentration-dependent manner. SHP-2 and Gab1 exist upstream of BMK1 and were activated by PDGF stimulation. PDGF also stimulated RASMC migration, which was inhibited by a transfection with dominant-negative MEK5. These findings suggest that BMK1 is involved in the pathogenesis of inflammatory vascular remodeling.3) In experiments using human umbilical vein endothelial cells (HUVEC), laminar fluid shear stress stimulated BMK1 activation. TNF-α stimulates c-Jun N-terminal kinase (INK) activation, which was inhibited by laminar flow. Physiological significance of BMK1 in endothelial cells has also confirmed. From these in vivo and in vitro findings, BMK1 is suggested to be involved in vascular injury in metabolic syndrome and BMK1 may be one of the drug targets for treatment of metabolic syndrome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Pramipexol protecxts against H_2O_2-induced PC12 cell death
普拉克索可防止 H_2O_2 诱导的 PC12 细胞死亡
DOI:
--
发表时间:
2006
期刊:
Naunyn-Schmiedeberg's Arch.Pharmacol 372(4)
影响因子:
--
作者:
[Fujita Y, ほか]
通讯作者:
ほか
Effects of proteasome inhibitor on tunicamycin-, Thapsigargin-, and polyglutamine-induced ER stress and cell death in PC12 cells.
蛋白酶体抑制剂对衣霉素、毒胡萝卜素和聚谷氨酰胺诱导的 PC12 细胞内质网应激和细胞死亡的影响。
DOI:
--
发表时间:
2007
期刊:
影响因子:
--
作者:
[Hitoshi, Nakayama, et. al.]
通讯作者:
et. al.
DOI:
10.1681/asn.2005050519
发表时间:
2006-03-01
期刊:
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
影响因子:
13.6
作者:
[Kondo, Shuji, Shimizu, Maki, Kagami, Shoji]
通讯作者:
Kagami, Shoji
抗酸化フラボノイドとアルドステロン拮抗薬の動脈硬化抑制作用
抗氧化剂黄酮类化合物和醛固酮拮抗剂的抗动脉硬化作用
DOI:
--
发表时间:
2006
期刊:
脈管学 46(5)
影响因子:
--
作者:
[吉栖 正典, ほか, 吉栖 正典]
通讯作者:
吉栖 正典
Transactivation of fetal liver kinase-1/kinase-insert domain-containing receptor by lysophosphatidylcholine induces vascular endothelial cell proliferation.
溶血磷脂酰胆碱反式激活胎儿肝激酶-1/激酶插入结构域受体可诱导血管内皮细胞增殖。
DOI:
--
发表时间:
2006
期刊:
Endocrinology 147・3
影响因子:
--
作者:
[Yanagino S, Satoh M, Suzuki K, Sato Y., Fujita Y ほか]
通讯作者:
Fujita Y ほか
共 31 条
Investigation of the role of c-Src and MAP kinases in diabetic microangiopathy and development of the new molecular pharmacotherapy
-
批准号:23590306
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.41万
-
财政年份:2011
-
负责人:YOSHIZUMI Masanori
-
依托单位:
Investigation of the involvement of oxidative stress in metabolic syndrome and the development of new anti-oxidants
-
批准号:20590258
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.08万
-
财政年份:2008
-
负责人:YOSHIZUMI Masanori
-
依托单位:
Investigation of the pathophysiological significance of big mitogen-activated protein kinase 1 in diabetic microangiopathy for the development of molecular-targeted drugs
-
批准号:16590195
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.3万
-
财政年份:2004
-
负责人:YOSHIZUMI Masanori
-
依托单位:
Investigation of the pathophysiological significance of big mitogen-acivated protein kinase 1 in diabetic nephropathy for the development of molecular-targeted drugs
-
批准号:14570078
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$1.98万
-
财政年份:2002
-
负责人:YOSHIZUMI Masanori
-
依托单位:
海外基金